tbuckley/cabot-search huggingface dataset:
BIOLOGIC TEST OF MUMMIES BY SPECIFIC PRECIPITATION.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The effect of partial hepatectomy on tumor growth in rats: in vivo and in vitro studies*1
Authors: K DEJONG
Journal: Hepatology (1995)

Residual tumor in the remnant liver after partial hepatectomy (PH) for colorectal liver metastases is a serious clinical problem. This fact is reflected by the high number of recurrences after potentially curative liver resections. Liver regeneration, it appears, might influence the growth of remaining micrometastases in the liver. Using rats, we demonstrated enhancement of growth of a syngeneic colon carcinoma (CC 531) in the remnant liver after 70% PH. Fourteen days after PH, tumor weights in the liver were twice as high as those of sham-operated rats. This difference in tumor weight was not found in extrahepatic tumors. In vitro experiments did not show stimulation of cultured CC 531 cells by portal or systemic serum withdrawn 24 hours or 14 days after hepatectomy as compared with sera obtained after sham operation. Co-cultures of CC 531 cells and hepatocytes (in ratios of 1: 10 or 1: 1) demonstrated a higher 3H-thymidine incorporation than was the case in separately cultured cells. In co-cultures, bromodeoxyuridine (BrdU) incorporation in DNA was found primarily in CC 531 cells and rarely in hepatocytes. Cell density appeared to be of influence on 3 H-thymidine incorporation in co-cultures. Hepatocytes were found to have a stimulating effect on CC 531 cells in low-density cultures, whereas high-density cultures exhibited an inhibiting effect after a culture time of 120 hours. These results show that, depending on cell density in co-cultures, a paracrine stimulating influence of hepatocytes on this type of colon carcinoma cells (CC 531) might be responsible for the increased tumor growth in vivo.
Updated Results from a Cancer Research UK First in Man Phase I Trial of IMA950 (A NOVEL MULTI PEPTIDE VACCINE) Plus Gm-Csf in Patients with Newly Diagnosed Glioblastoma
Authors: A. James, P. Mulholland, S. Peoples, O. Al-Salihi, C. Twelves, S. Jefferies, S. Halford, J. Ritchie, H. Singh-Jasuja, R. Rampling
Journal: Annals of Oncology (2012)
Vincristine in the Treatment of Acute Leukemia in Children
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TURKEY
Journal: JAMA (1953)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Epidemiology of fulminant hepatitis A cases in Vienna - an informative case series
Authors: David JM Bauer, Stephan Aberle, Anna Farthofer, David Chromy, Benedikt Simbrunner, Dr. Lisa Steininger, Mattias Mandorfer, Ralf Schmidt, Michael Trauner, Robert Strassl, Florian Mayer, Heidemarie Holzmann, Thomas Reiberger
Journal: Journal of Hepatology (2020)
Costs and effects of long-term oral anticoagulant treatment after myocardial infarction
Authors: P. F. van Bergen
Journal: JAMA (1995)

<h3>Objective.</h3> —To investigate the costs and effects of long-term oral anticoagulant treatment after myocardial infarction. <h3>Design.</h3> —Cost-effectiveness analysis, based on a randomized, double-blind, placebo-controlled trial. <h3>Setting.</h3> —Sixty Dutch hospitals. <h3>Patients.</h3> —A total of 3404 hospital survivors of acute myocardial infarction randomized within a median period of 4 days after discharge to either oral anticoagulant treatment or placebo. The mean follow-up was 37 months. <h3>Intervention.</h3> —Oral anticoagulant treatment aimed at a target international normalized ratio of 2.8 to 4.8. <h3>Main Outcome Measurements.</h3> —Costs of hospital stay during readmissions, costs related to major cardiologic interventions, and costs of oral anticoagulant treatment. <h3>Results.</h3> —The costs of oral anticoagulant treatment were estimated at 394 Dutch guilders (Dfl) per patient-year (Dfl1=US $0.58). Placebo patients stayed 18 830 days in the hospital compared with 15 083 days for anticoagulation patients. Average costs per patient of medical care during follow-up were estimated at Dfl 10784 for placebo patients and Dfl 9878 for anticoagulation patients. <h3>Conclusions.</h3> —Costs of long-term anticoagulant treatment are outweighed by the costs of prevented clinical events. (<i>JAMA</i>. 1995;273:925-928)
Pfluegers Arch f d Ges Physiologie, Berlin
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Nephrotic syndrome caused by probenecid
Authors: A. Sokol
Journal: JAMA (1967)

IN 1961, Ferris and co-workers in reporting the first case of the nephrotic syndrome caused by probenecid<sup>1</sup>mentioned a number of drugs—including trimethadione, paramethadione, mercurials, tolbutamide, sodium perchlorate, and phenylbutazone (Butazolidin)—administration of which resulted in a similar untoward occurrence. A second case of nephrotic syndrome which occurred after use of probenecid has been seen in this hospital. <h3>Report of a Case</h3> A 34-year-old white man was first seen at his physician's office in late 1962 with a chief complaint of arthritis which was diagnosed as gout because of hyperuricemia and an excellent response to colchicine. Results of routine urine examination were normal. On Nov 2, 1963, the patient was placed on a regimen of probenecid, 0.5 gm twice a day. He was not seen again until Jan 30, 1964, when he complained of facial edema, headaches, and dizziness on standing. Following hospitalization, it was discovered that he had mild
The Weekly Medical Review.
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Regularization and stylization of medical records
Authors: B. L. Gordon
Journal: JAMA (1970)

<i>Medical documentation and transmission are impaired because of failures in the selection and tabulation of significant data at the source. Excessive narrative and lack of preciseness and specificity in the presentations pose serious difficulties in reference and interpretation. Suggestions for improvement evolved during the development of computer-oriented</i>Current Medical Information and Terminology (CMIT).<i>The</i>Medical Record Form (MRF)<i>is patterned after</i>CMIT<i>"worksheets" as used in the preparation of abstracts of textbooks and specialty journals</i>. CMIT<i>methodology is adaptable for</i>MRF<i>purposes, ie, in developing effective summaries of basic medical records to complement the original record, and to serve as input for computerization such as storage, indexing, retrieval, matching, "differential diagnosis," and possible applications in data base development</i>.
Partial Muscle Carnitine Palmitoyltransferase-A Deficiency
Authors: Nathan S. Ross
Journal: JAMA (1987)

After initiation of ibuprofen therapy, a 45-year-old woman developed muscle weakness and tenderness with rhabdomyolysis, culminating in respiratory failure. A muscle biopsy specimen showed a vacuolar myopathy, and markedly decreased muscle carnitine content and carnitine palmitoyltransferase activity. Following recovery, muscle carnitine content was normal but carnitine palmitoyltransferase activity was still abnormally low. The ratio of palmitoyl— coenzyme A plus carnitine to palmitoylcarnitine oxidation by muscle mitochondria isolated from the patient was markedly decreased. We conclude that transiently decreased muscle carnitine content interacted with partial deficiency of carnitine palmitoyltransferase-A to produce rhabdomyolysis and respiratory failure and that ibuprofen may have precipitated the clinical event. (<i>JAMA</i>1987:257:62-65)
Licensure reciprocity
Authors: A. R. Holder
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Resistance to High-fat Diet-Induced Obesity and Insulin Resistance in Mice with Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
Authors: Dongyan Zhang, Jennifer Christianson, Zhen-Xiang Liu, Liqun Tian, Cheol Soo Choi, Susanne Neschen, Jianying Dong, Philip A. Wood, Gerald I. Shulman
Journal: Cell Metabolism (2010)
Air Pollution and Daily Mortality in Erfurt, East Germany, 1980-1989
Authors: Claudia Spix, Joachim Heinrich, Douglas Dockery, Joel Schwartz, Gisela Volksch, Kurt Schwinkowski, Christel Collen, H. Erich Wichmann
Journal: Environmental Health Perspectives (1993)

In Erfurt, Germany, unfavorable geography and emissions from coal burning lead to very high ambient pollution (up to about 4000 micrograms/m3 SO2 in 1980-89). To assess possible health effects of these exposures, total daily mortality was obtained for this same period. A multivariate model was fitted, including corrections for long-term fluctuations, influenza epidemics, and meterology, before analyzing the effect of pollution. The best fit for pollution was obtained for log (SO2 daily mean) with a lag of 2 days. Daily mortality increased by 10% for an increase in SO2 from 23 to 929 micrograms/m3 (5% quantile to 95% quantile). A harvesting effect (fewer people die on a given day if more deaths occurred in the last 15 days) may modify this by +/- 2%. The effect for particulates (SP, 1988-89 only) was stronger than the effect of SO2. Log SP (daily mean) increasing from 15 micrograms/m3 to 331 micrograms/m3 (5% quantile to 95% quantile) was associated with a 22% increase in mortality. Depending on harvesting, the observable effect may lie between 14% and 27%. There is no indication of a threshold or synergism. The effects of air pollution are smaller than the effects of influenza epidemics and are of the same size as meterologic effects. The results for the lower end of the dose range are in agreement with linear models fitted in studies of moderate air pollution and episode studies.
Alcoholism
Authors: E. End
Journal: JAMA (1973)

<h3>To the Editor.—</h3> The thoughtful letters of Lew (223:800, 1973), of Buchan, and of Levitt and Weedman (224:526, 1973) on alcoholism make stimulating but rather discouraging reading, and bring up a question. Until we have a sure cure for this, our No. 1 drug abuse problem, shouldn't we direct more effort toward deglamorizing drinking? Shouldn't our great, good, protective government, which tells us how to practice medicine and decrees which medications we can and cannot use, get on the stick and stop all advertising of drinking as a passport to Happiness in Life, Acceptance in Society, and Success in Business? How ironic it is for magazines, billboards, and newspapers to bombard us with seductive advertisements for alcohol, our most dangerous addicting drug, which is available by over-the-counter sale, while our ever-more-obese population is apparently to be doomed to fight alone against the frustration, emotional trauma, and hypercholesteremia of overweight because the
Prospective Study of Exposure to Environmental Tobacco Smoke and Dysmenorrhea
Authors: Changzhong Chen, Sung-Il Cho, Andrew I. Damokosh, Dafang Chen, Guang Li, Xiaobin Wang, Xiping Xu
Journal: Environmental Health Perspectives (2000)

Dysmenorrhea is a common gynecologic disorder in women of reproductive age. Previous studies have found an association between current cigarette smoking and prevalence of dysmenorrhea. This study investigated the association between exposure to environmental tobacco smoke (ETS) and the occurrence of dysmenorrhea among women without a history of this disorder. The study population consisted of 165 newly wed, nonsmoking Chinese women (in Shenyang, China), who intended to get pregnant and who had no past history of dysmenorrhea at the time of enrollment. These women completed a baseline questionnaire interview upon enrollment and were prospectively followed by daily diary. Dysmenorrhea was defined as a diary recording of abdominal pain or low back pain for at least 2 days during a menstrual period. A subject's ETS exposure was defined as the mean number of cigarettes smoked per day at home by household members over an entire menstrual cycle before the menstrual period. A logistic regression model was used to assess the effect of ETS on the risk of dysmenorrhea, with adjustment for age, body mass index, education, season, area of residence, occupation, shift work, perceived stress, passive smoking at work, and occupational exposure to chemical hazards, dust, and noise. Generalized estimating equations were used to account for autocorrelations as a result of multiple cycles per subject. This report is based on 625 prospectively followed menstrual cycles with complete baseline and diary data. ETS exposure was reported in 77% of cycles, within which average daily exposures throughout the cycle ranged from 0.02 to 10. 3 cigarettes. The incidence of dysmenorrhea was 9.7% and 13.3% among nonexposed and exposed cycles, respectively. Among ETS-exposed cycles, there was a positive dose-response relationship between the numbers of cigarettes smoked and the relative risk of dysmenorrhea. The adjusted odds ratios of dysmenorrhea associated with "low," "middle," and "high" tertiles of ETS exposure versus no exposure were 1.1 [95% confidence interval (CI), 0.5-2.6], 2.5 (CI, 0.9-6.7), and 3.1 (CI, 1.2-8.3), respectively. The findings were consistent with those of analyses limited to the first follow-up menstrual cycle from each woman. These data suggest a significant dose-response relationship between exposure to ETS and an increased incidence of dysmenorrhea in this cohort of young women.
Prediction of advanced fibrosis with transient elastography is superior to gut microbiota-based approaches in non-alcoholic fatty liver disease
Authors: Sonja Lang, Fedja Farowski, Anna Martin, Hilmar Wisplinghoff, Maria J.G.T. Vehreschild, Marcin Krawczyk, Angela Nowag, Anne Kretschmar, Claus Jürgen Scholz, Philipp Kasper, Christoph Roderburg, Frank Lammert, Tobias Goeser, Hans-Michael Steffen, Münevver Demir
Journal: Journal of Hepatology (2020)
Chimeric antigen receptor (CAR<sup>+</sup>) modified T cells targeting prostate-specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC).
Authors: Susan F. Slovin, Xiuyan Wang, Melanie Hullings, Gabrielle Arauz, Shirley Bartido, Jason Stuart Lewis, Heiko Schöder, Pat Zanzonico, Howard I. Scher, Michel Sadelain, Isabelle Riviere
Journal: Journal of Clinical Oncology (2013)

72 Background: A phase I dose-escalating study to assess safety, dose and targeting efficiency of genetically modified autologous human T cells targeted to PSMA was initiated. Preclinical models demonstrated anti-tumor activity and accumulation, migration, and persistence of these cells to tumor. The autologous PSMA-targeted T cells utilizes the P28z second generation chimeric antigen receptor following iv cyclophosphamide (Cy). For safety, the herpes simplex virus-1 thymidine kinase (hsvtk) gene is co-expressed with the P28z receptor, rendering T cells sensitive to ganciclovir for immediate T cell elimination. The expression of hsvtk enables PET imaging using radiolabeled FIAU to localize these T cells. Methods: Autologous T cells are activated from a leukapheresis product using anti-CD3/CD28 Dynabeads. Release criteria include mean vector copy number by Q-PCR and vector identity by Southern blot, absence of Replication Competent Retrovirus and residual Dynabeads. Pts were dosed from 10 7 to 3 x 10 7 CAR + T cells/kg. All 7 pts received 300mg/m 2 of Cy one day before infusion. Baseline and post treatment imaging included FDG, FDHT and 18 F-FIAU PET scans. Results: Three pts in cohort 1 received 1 x 10 7 CAR + T cells/kg safely. A fourth pt received the same dose with a modified vector with higher copy number. One pt had stable disease for &gt; 6 months; a second pt has stable scans for &gt; 16 months; the third and fourth patients progressed. Of 3 pts in cohort 2, one received 1.5 x 10 7 CAR + T cells/kg and 2 received 3 x 10 7 CAR + cell/kg. All 3 had intermittent fever spikes up to 39 o C associated with increased levels of IL-4, IL-8, IP-10, sIL-2ra and IL-6 suggesting T cell activation. CAR + cells persisted in the circulation for up to 2 weeks. Scans with 18 F-FIAU labeling suggests that imaging may be cell dose dependent. Conclusions: We have shown that pts can be safetly treated with an ex vivo transduction, expansion and therapeutic protocol for the generation of PSMA targeted T cells. Cytokine production suggests activation of these T cells with their persistence in blood for up to 2 weeks. If imaging with FIAU is suboptimal, a second cohort of pts will be studied with 124 I- FIAU. Clinical trial information: NCT01140373.